摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-oxo-adamantan-2-ylamine ethylene ketal | 717890-60-3

中文名称
——
中文别名
——
英文名称
6-oxo-adamantan-2-ylamine ethylene ketal
英文别名
Spiro[1,3-dioxolane-2,6'-adamantane]-2'-amine
6-oxo-adamantan-2-ylamine ethylene ketal化学式
CAS
717890-60-3
化学式
C12H19NO2
mdl
——
分子量
209.288
InChiKey
SFTZQUHFBODRKC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    44.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    6-oxo-adamantan-2-ylamine ethylene ketal2-methyl-2-phenylpropanoyl chloride三乙胺 作用下, 以 二氯甲烷 为溶剂, 以50%的产率得到N-(6-oxo-adamantan-2-yl)-2-phenyl-isobutyramide ethylene ketal
    参考文献:
    名称:
    [EN] ADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS
    [FR] ADAMANTYL ACETAMIDES UTILISES COMME INHIBITEURS DE LA HYDROXYSTEROIDE DESHYDROGENASE
    摘要:
    公式(I)N-氧化物形式,其药学上可接受的加盐和立体化学异构体形式,其中n表示整数1或2;R1和R2分别表示氢C1-4烷基,NR9R10,C1-4烷氧基;或者R1和R2与它们连接的碳原子一起形成C3-6环烷基;当n为2时,R1或R2中的任一者可以缺失以形成不饱和键;R3表示C6-12环烷基,优选选择自环辛基和环己基,或者R3表示具有以下公式之一的一价基团(a)(b)(c)(l)(q)(r)(g)(u)(o)(w)(j)(k)(t),其中所述C6-12环烷基或一价基团可以选择性地用来自C1-4烷基,C1-4烷氧基,卤素或羟基的一个,或可能是两个,三个或更多个取代基取代;Q表示Het1或Ar2,其中所述C3-8环烷基,Het1或Ar2可以选择性地用来自卤素,C1-4烷基,C1-4烷氧基,羟基,硝基,NR5R6,C1-4烷氧基的一个,或可能是两个,三个或更多个取代基,每个独立选自羟基羰基,Het2和NR7R8,以及C1-4烷基的一个,或可能是两个或三个卤素取代基,优选三氟甲基;R5和R6各自独立地表示氢,C1-4烷基,或用苯基取代的C1-4烷基;R7和R8各自独立地表示氢或C1-4烷基;R9和R10各自独立地表示氢,C1-4烷基或C1-4烷氧羰基;L表示C1-4烷基;Het1表示从吡啶基,噻吩基或1,3-苯并二氧杂环烷中选择的杂环;Het2表示哌啶基,吡咯烷基或吗啉基;Ar2表示苯基,萘基或茚基。
    公开号:
    WO2004056744A1
  • 作为产物:
    描述:
    6-hydroxyimino-adamantan-2-yl ethylene ketal 在 氢气 作用下, 以 为溶剂, 生成 6-oxo-adamantan-2-ylamine ethylene ketal
    参考文献:
    名称:
    [EN] ADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS
    [FR] ADAMANTYL ACETAMIDES UTILISES COMME INHIBITEURS DE LA HYDROXYSTEROIDE DESHYDROGENASE
    摘要:
    公式(I)N-氧化物形式,其药学上可接受的加盐和立体化学异构体形式,其中n表示整数1或2;R1和R2分别表示氢C1-4烷基,NR9R10,C1-4烷氧基;或者R1和R2与它们连接的碳原子一起形成C3-6环烷基;当n为2时,R1或R2中的任一者可以缺失以形成不饱和键;R3表示C6-12环烷基,优选选择自环辛基和环己基,或者R3表示具有以下公式之一的一价基团(a)(b)(c)(l)(q)(r)(g)(u)(o)(w)(j)(k)(t),其中所述C6-12环烷基或一价基团可以选择性地用来自C1-4烷基,C1-4烷氧基,卤素或羟基的一个,或可能是两个,三个或更多个取代基取代;Q表示Het1或Ar2,其中所述C3-8环烷基,Het1或Ar2可以选择性地用来自卤素,C1-4烷基,C1-4烷氧基,羟基,硝基,NR5R6,C1-4烷氧基的一个,或可能是两个,三个或更多个取代基,每个独立选自羟基羰基,Het2和NR7R8,以及C1-4烷基的一个,或可能是两个或三个卤素取代基,优选三氟甲基;R5和R6各自独立地表示氢,C1-4烷基,或用苯基取代的C1-4烷基;R7和R8各自独立地表示氢或C1-4烷基;R9和R10各自独立地表示氢,C1-4烷基或C1-4烷氧羰基;L表示C1-4烷基;Het1表示从吡啶基,噻吩基或1,3-苯并二氧杂环烷中选择的杂环;Het2表示哌啶基,吡咯烷基或吗啉基;Ar2表示苯基,萘基或茚基。
    公开号:
    WO2004056744A1
点击查看最新优质反应信息

文献信息

  • ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS
    申请人:Linders Theodorus Maria Joannes
    公开号:US20080096869A1
    公开(公告)日:2008-04-24
    the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents an integer being 1 or 2; R 1 and R 2 each independently represents hydrogen C 1-4 alkyl, NR 9 R 10 , C 1-4 alkyloxy; or R 1 and R 2 taken together with the carbon atom with which they are attached form a C 3-6 cycloalkyl; and where n is 2, either R 1 or R 2 may be absent to form an unsaturated bond; R 3 represents a C 6-12 cycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or R 3 represents a monovalent radical having one of the following formulae wherein said C 6-12 cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C 1-4 alkyl, C 1-4 alkyloxy, halo or hydroxy; Q represents Het 1 or Ar 2 wherein said C 3-8 cycloalkyl, Het 1 or Ar 2 are optionally substituted with one or where possible two or more substituents selected from halo, C 1-4 alkyl, C 1-4 alkyloxy, hydroxy, nitro, NR 5 R 6 , C 1-4 alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het 2 and NR 7 R 8 , and C 1-4 alkyl substituted with one or where possible two or three halo substituents, preferably trifluoromethyl; R 5 and R 6 each independently represent hydrogen, C 1-4 alkyl, or C 1-4 alkyl substituted with phenyl; R 7 and R 8 each independently represent hydrogen or C 1-4 alkyl; R 9 and R 10 each independently represent hydrogen, C 1-4 alkyl or C 1-4 alkyloxycarbonyl; L represents C 1-4 alkyl; Het 1 represents a heterocycle selected from pyridinyl, thiophenyl, or 1,3-benzodioxolyl; Het 2 represents piperidinyl, pyrrolidinyl or morpholinyl; Ar 2 represents phenyl, naphtyl or indenyl.
  • US7332524B2
    申请人:——
    公开号:US7332524B2
    公开(公告)日:2008-02-19
  • US7968601B2
    申请人:——
    公开号:US7968601B2
    公开(公告)日:2011-06-28
  • [EN] ADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS<br/>[FR] ADAMANTYL ACETAMIDES UTILISES COMME INHIBITEURS DE LA HYDROXYSTEROIDE DESHYDROGENASE
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2004056744A1
    公开(公告)日:2004-07-08
    formulae (I)the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents an integer being 1 or 2; R1 and R2 each independently represents hydrogen C1-4alkyl, NR9R10, C1-4alkyloxy; or R1 and R2 taken together with the carbon atom with which they are attached form a C3-6cycloalkyl; and where n is 2, either R1 or R2 may be absent to form an unsaturated bond; R3 represents a C6-12cycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or R3 represents a monovalent radical having one of the following formulae(a) (b) (c) (l) (q) (r) (g) (u) (o) (w) (j) (k) (t) wherein said C6-12cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C1-4alkyl, C1-4alkyloxy, halo or hydroxy; Q represents Het1 or Ar2 wherein said C3-8cycloalkyl, Het1 or Ar2 are optionally substituted with one or where possible two or more substituents selected from halo, C1-4alkyl, C1-4alkyloxy, hydroxy, nitro, NR5R6, C1-4alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het2 and NR7R8, and C1-4alkyl substituted with one or where possible two or three halo substituents, preferably trifluoromethyl; R5 and R6 each independently represent hydrogen, C1-4alkyl, or C1-4alkyl substituted with phenyl; R7 and R8 each independently represent hydrogen or C1-4alkyl; R9 and R10? each independently represent hydrogen, C1-4alkyl or C1-4alkyloxycarbonyl; L represents C1-4alkyl; Het1 represents a heterocycle selected from pyridinyl, thiophenyl, or 1,3-benzodioxolyl; Het2 represents piperidinyl, pyrrolidinyl or morpholinyl; Ar2 represents phenyl, naphtyl or indenyl.
    公式(I)N-氧化物形式,其药学上可接受的加盐和立体化学异构体形式,其中n表示整数1或2;R1和R2分别表示氢C1-4烷基,NR9R10,C1-4烷氧基;或者R1和R2与它们连接的碳原子一起形成C3-6环烷基;当n为2时,R1或R2中的任一者可以缺失以形成不饱和键;R3表示C6-12环烷基,优选选择自环辛基和环己基,或者R3表示具有以下公式之一的一价基团(a)(b)(c)(l)(q)(r)(g)(u)(o)(w)(j)(k)(t),其中所述C6-12环烷基或一价基团可以选择性地用来自C1-4烷基,C1-4烷氧基,卤素或羟基的一个,或可能是两个,三个或更多个取代基取代;Q表示Het1或Ar2,其中所述C3-8环烷基,Het1或Ar2可以选择性地用来自卤素,C1-4烷基,C1-4烷氧基,羟基,硝基,NR5R6,C1-4烷氧基的一个,或可能是两个,三个或更多个取代基,每个独立选自羟基羰基,Het2和NR7R8,以及C1-4烷基的一个,或可能是两个或三个卤素取代基,优选三氟甲基;R5和R6各自独立地表示氢,C1-4烷基,或用苯基取代的C1-4烷基;R7和R8各自独立地表示氢或C1-4烷基;R9和R10各自独立地表示氢,C1-4烷基或C1-4烷氧羰基;L表示C1-4烷基;Het1表示从吡啶基,噻吩基或1,3-苯并二氧杂环烷中选择的杂环;Het2表示哌啶基,吡咯烷基或吗啉基;Ar2表示苯基,萘基或茚基。
查看更多